Category: Press Releases

LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) — Firefly Games Inc. announced today that they have partnered with MGA Entertainment to launch a global L.O.L Surprise!™ Room Makeover mobile game coming this summer on all iOS and Android devices. This partnership was established through the multiple brand licensing deal between MGA Entertainment and Riva Technology and Entertainment (RTE) that was announced recently. Beloved fans of L.O.L Surprise!™ will now be able to experience their favorite toy in a fresh new way with L.O.L Surprise!™ Room Makeover.

L.O.L Surprise!™ Room Makeover boasts a unique blend of Match-3 gameplay with the ability to decorate different themed rooms as well as incorporating the brand’s iconic trademark of unboxing L.O.L Surprise!™ Balls, and more! The Firefly team is already in the works of planning post-launch features and new content to further captivate existing fans.

“We have been working on some great Hollywood movie IPs over the years, now we see an expansion opportunity to diversify and leverage our current strengths into toy brands,” said Michael Zhang, CEO of Firefly Games. “MGA is a great partner to work with and we are hoping to add additional value to the brand and the players. It also could be a good chance for us to build our own metaverse with this IP.”

“Digital games are an important way to build community and ensure that our fans feel connected to the L.O.L Surprise!™ lifestyle,” says Isaac Larian, CEO & Founder of MGA.

The company is seeking to publish L.O.L Surprise! Room Makeover globally on July 1, 2021.

About Firefly Games 
Firefly Games, founded in 2015, is a mobile game publisher and developer for the global iOS and Android market. The Firefly team are not only experts in the mobile gaming space, but they have immense experience working with major studios and brands for world-renowned intellectual properties (IP) from Skydance Media, Dreamworks Animation, NBC Universal, and now MGA Entertainment on creating the perfect games for beloved IP.

About MGA Entertainment 
MGA Entertainment, Inc., a consumer entertainment products company headquartered in Chatsworth, California creates innovative proprietary and licensed products including toys and games, dolls, consumer electronics, home décor, stationery and sporting goods. The MGA family includes award winning brands such as L.O.L. Surprise!™, Little Tikes®, Bratz®, LaLaLoopsy™, Secret Crush™, Tobi™ Robot Smartwatch, Rainbow High™, Poopsie Slime Surprise!™, Sing-a-Long Lilly and Ami, Rescue Tales™, VIRO Rides™, Na! Na! Na! Surprise™ and Zapf Creation®. Visit us at www.mgae.com.

About Riva Technology and Entertainment:
Founded in 2002, with a global presence stretching from the USA to East Asia, RTE has successfully been delivering the vision of tomorrow for close to 20 years. RTE’s group of companies hold an industry advantage in their ability to take every project from concept to execution, all housed under one roof. The complementary companies cover location-based entertainment, brand and Intellectual Property licensing, content development, consumer products, gaming, and esports.

Contact:
Michael Zhang
michael.zhang@fireflygames.com

Amanda Gazali
amanda.gazali@fireflygames.com

 

• In recognition of its 10 million Invisalign smiles milestone, Align donated $10 million to the Align Foundation donor-advised fund, which has now funded US$1 million to Operation Smile
• Previously announced campaign “10 Million Smiles. 10 Million Thanks” centers on the transformative power of Invisalign treatment through the eyes of Invisalign patients
• Align hopes to inspire others to share their smiles with the world using #10MInvisalignSmiles

TEMPE, Ariz., June 17, 2021 (GLOBE NEWSWIRE) — Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the Align Foundation, the Company’s donor-advised fund through Fidelity Charitable, has donated US$1 million to Operation Smile, a global surgical nonprofit, to help children around the world born with cleft conditions receive safe, effective, and timely cleft surgery and comprehensive care.

“Operation Smile’s mission strongly resonates with Align’s purpose of transforming smiles and changing lives,” said Raj Pudipeddi, chief innovation, product and marketing officer and senior vice president, Align Technology. “We are proud to support a future where more smiles can be transformed through safe surgery and medical treatment – and hope to inspire others through our donation to help Operation Smile change the lives of more children.”

The “10 Million Smiles. 10 Million Thanks” campaign is based on the transformative power of Invisalign treatment as seen through the eyes of Invisalign patients. The donation to Operation Smile builds on that goal and aims to help more children around the world to smile by raising awareness and generating support and funding for Operation Smile. Operation Smile provides surgery and ongoing care for people affected by cleft lip and cleft palate in resource-limited environments.

“We are so appreciative of the dedication and support from Align Technology over the years and are excited for what we can do to bring families renewed hope, and help children around the world smile even more as a result of this latest donation,” said Kristie Magee Porcaro, chief strategy officer, Operation Smile. “Together, we’re improving the health of many children and ensuring that they have the opportunity for a better future.”

Align Technology initiated a wave of photo sharing activity by asking its followers on social media channels around the world to share their smiles and to help change a child’s life using #10MInvisalignSmiles. The Company is working with Operation Smile and Invisalign ambassadors and regional stakeholders to encourage their communities of followers to join with them in the awareness campaign. Tag yourself using #10MInvisalignSmiles and help Align increase awareness of Operation Smile and its global mission. To learn more, please visit: www.10MInvisalignSmiles.com

For information about Operation Smile, please visit http://www.operationsmile.org

About Operation Smile
Operation Smile revolutionized cleft surgery globally in 1982. With nearly four decades of experience as one of the largest surgical volunteer-based nonprofits, Operation Smile staff, its private-public partnerships and thousands of volunteers have improved the health and dignity of patients with cleft conditions, helping them to better breathe, eat, speak and live lives of greater quality and confidence. While one cleft surgery can bring immediate transformation to a child’s life in as little as 45 minutes, Operation Smile is committed to providing patients with health that lasts—being there to offer patients additional surgeries, dentistry, psychological services, speech therapy and other essential cleft treatments. Its training and education programs elevate local surgical standards and entire health systems to aid safe surgery and strengthen a global network to reach more people earlier in their lives. You can learn more about its transformative and healing work by visiting www.operationsmile.org or by following @operationsmile on social media.

The Align Foundation
Launched in 2020, the Align Foundation provides a structured means by which significant donations are directed from a donor-advised fund overseen by Fidelity Charitable, with the flexibility to provide smaller monetary donations, processes to donate our products, as well as an organized way to involve our employees in giving activities. In March 2020, we funded $1 million to support COVID-19 relief efforts globally and donated personal protective equipment (PPE) such as N95 masks and worked with partners to source supplies for additional PPE to help hospitals and healthcare providers. To date, Align has contributed over $4.6 million to charitable causes including Operation Smile, America’s Toothfairy, and other non-profits dedicated to youth development through schools and educational programs. Over the last two years, our employees have volunteered over 10,000 hours as part of our dedicated month of giving in October called Month of Smiles.

About Align Technology, Inc.
Align Technology designs, manufactures and offers the Invisalign system, the most advanced clear aligner system in the world, iTero intraoral scanners and services, and exocad CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 200 thousand doctor customers and is key to accessing Align’s 500 million consumer market opportunity worldwide. Align has helped doctors treat over 10.2 million patients with the Invisalign system and is driving the evolution in digital dentistry through the Align Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit http://www.exocad.com.

Align Investor Relations	Zeno Group
Madelyn Homick	Sarah Johnson
(408) 470-1180	(828) 551-4201
mhomick@aligntech.com	sarah.johnson@zenogroup.com

VICTOR, N.Y., June 17, 2021 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that it has acquired a minority stake in Dos Hombres, an artesanal and hand-crafted mezcal brand created by Breaking Bad co-stars Aaron Paul and Bryan Cranston. The investment was made through Constellation’s venture capital group, and Dos Hombres remains independently owned and will continue to manage, market, and produce its award-winning mezcals.

 

SAN DIEGO and PARIS, June 17, 2021 (GLOBE NEWSWIRE) — Rancho Santa Fe Bio, Inc. (“RSF Bio” or the “Company”), a San Diego, California-based clinical-stage cardiovascular platform company, today announced that it has entered into an exclusive worldwide license agreement with Sanofi, a global biopharmaceutical company. This agreement provides RSF Bio with Sanofi’s rights to Ataciguat. With this license, RSF Bio will have the rights it needs to continue development of Ataciguat through clinical trials in the United States and potentially in select international countries.

Before signing this license agreement, RSF Bio entered into a worldwide exclusive license agreement in December 2019 with Mayo Clinic for the use of Ataciguat in the treatment of patients with calcific aortic valve stenosis (“CAVS”). Under that license, Mayo Clinic assigned to RSF Bio its US IND No. 119,829 along with additional patents, patent applications and know-how.

CAVS is a progressive disease that afflicts predominately the older populations with a prevalence of 2% in patients over the age of 55 years. Its prevalence increases with age to approximately 12% or higher in populations >75 years of age. (Osnabrugge et al., J Am Coll Cardiol. 2013 and Faggiano et al., Am J Cardiol. 2003). CAVS is characterized by hardening of the aortic leaflets, which progresses over years and is predominately due to a maladaptive process of calcium deposition in the valves. CAVS is often fatal within a few years from symptom onset, if untreated. Currently, no medical treatment has been proven to be effective, and the treatment of choice for severe disease is aortic valve replacement, either by surgical aortic valve replacement (“SAVR”) or transcatheter aortic valve replacement (“TAVR”). RSF Bio is currently in an advanced stage of development of a novel pharmaceutical treatment with the drug Ataciguat, building upon a Phase IIb clinical trial. RSF Bio is also in the early planning stages of studying application for Ataciguat in certain other uses and indications.

Sanofi originally investigated Ataciguat in numerous preclinical studies and conducted clinical trials with the drug involving over 1,000 patients in total for three different indications: (a) stable angina, (b) peripheral arterial disease and (c) neuropathic pain. Following a reprioritization of its research and development pipeline, Sanofi provided Ataciguat to the New Therapeutic Uses (“NTU”) program at the U.S. National Institutes of Health’s National Center for Advancing Translational Sciences Program (“NCATS”). This program is designed to encourage the application of repurposed drugs into other clinical trials. The laboratory of Jordan Miller, Ph.D., at Mayo Clinic focuses on mechanisms underlying the progression of calcium build-up in CAVS. He was awarded a grant through the NCATS program to conduct preclinical studies with Ataciguat in CAVS, followed by Phase I and Phase II clinical trials at Mayo Clinic.

“The NCATS New Therapeutic Uses program developed and disseminated innovative approaches to three-way collaborations between government, pharmaceutical companies and academic medical centers to accelerate treatment development,” said Christine Colvis, Ph.D., Director of Drug Development Partnership Programs at NCATS. “The negotiation process to set up collaborative research agreements is a bottleneck in the establishment of public-private partnerships. The NTU template legal agreements provided a strong launching point for the negotiations, speeding the process,” she added. “We are excited to see the goals of the program being realized through the successful progression of this project by RSF Bio to potentially Phase III clinical testing and the promise it holds to deliver better treatment options to patients suffering from CAVS.”

“We are pleased about the potential of Ataciguat and the benefit it may offer to people suffering from CAVS,” said Alban de La Sablière, Senior Vice President, Head of Sanofi Partnering.  “After a reprioritization of our portfolio, we made a decision to repurpose this asset with NCATS and Mayo Clinic for Phase I and Phase II clinical trials and now with RSF Bio in order to advance science and bring treatment options to patients with this unmet medical need.”

“This has been an exciting journey so far, from the support we received from NCATS, to our extensive interactions and close partnerships with Sanofi, and now continuing advancement of Ataciguat towards clinical use with RSF Bio,” says Dr. Jordan Miller, the Chair of the Scientific Advisory Board of RSF Bio. “I am confident that the RSF Bio team will continue the advancement of therapies for CAVS and investigating applications of Ataciguat in other indications.”

“We are excited about adding the Sanofi rights to those which we have already received from Mayo Clinic through its NCATS funding,” said Randy Berholtz, the Chair and Chief Executive Officer of RSF Bio. “We believe we now have all of the pieces necessary to move Ataciguat along to the next level of clinical trials in the United States and internationally. We are happy to work with Mayo Clinic Venture’s team and to have Dr. Miller as Chair of our Scientific Advisory Board. We look forward to collaborating with them and him on this effort involving Ataciguat in CAVS,” he continued.

About Ataciguat
Ataciguat is a novel anthranilic acid derivative that belongs to a structural class of sGC activators that can activate the oxidized form of sGC. Ataciguat has been developed through a collaboration involving Sanofi, NCATS and Mayo Clinic. Ataciguat has undergone extensive pre-clinical and clinical development including Phase I and Phase II clinical trials at Mayo Clinic for treatment of the progression of CAVS. The drug and its application in CAVS is now licensed to RSF Bio for further development through clinical trials and if successful, for future commercialization.

About Rancho Santa Fe Bio, Inc.
RSF Bio is a San Diego, California clinical stage cardiovascular platform company. RSF Bio has exclusively licensed from the Mayo Clinic and from Sanofi Ataciguat for the treatment of the progression of CAVS. RSF Bio is also involved in developing additional indications for Ataciguat, developing AVS biomarkers and in conducting research and development of additional small molecules drugs in the cardiovascular and other fields. RSF Bio’s website is www.rsfbio.com and for more information please contact the Company at info@rsfbio.com.

New partnership between General Fusion and UKAEA is a landmark collaboration in the development of fusion, a technology for the world’s low-carbon future

VANCOUVER, Canada and LONDON, UK, June 17, 2021 (GLOBE NEWSWIRE) — (BST) — The UK Atomic Energy Authority (UKAEA) and General Fusion have announced an agreement under which General Fusion will build and operate its Fusion Demonstration Plant (FDP) at UKAEA’s Culham Campus. General Fusion will enter into a long-term lease with UKAEA following construction of a new facility at Culham to host the FDP. The FDP will demonstrate General Fusion’s proprietary Magnetized Target Fusion (MTF) technology, paving the way for the company’s subsequent commercial pilot plant. General Fusion will benefit from the cluster of fusion supply chain activities in the UK, centered on UKAEA’s globally recognized expertise and presence in the field.

Amanda Solloway, Science Minister for UK Government said: “This new plant by General Fusion is a huge boost for our plans to develop a fusion industry in the UK, and I’m thrilled that Culham will be home to such a cutting-edge and potentially transformative project. Fusion energy has great potential as a source of limitless, low-carbon energy, and today’s announcement is a clear vote of confidence in the region and the UK’s status as a global science superpower.”

The Fusion Demonstration Plant at Culham is the culmination of more than a decade of advances in General Fusion’s technology, and represents a major milestone on the company’s path to commercialization. The Fusion Demonstration Plant will verify that General Fusion’s MTF technology can create fusion conditions in a practical and cost-effective manner at power plant relevant scales, as well as refine the economics of fusion energy production, leading to the subsequent design of a commercial fusion pilot plant. Construction is anticipated to begin in 2022, with operations beginning approximately three years later.

General Fusion and UKAEA intend to collaborate on a range of fusion energy technologies for power plant design and operation.

“Coming to Culham gives us the opportunity to benefit from UKAEA’s expertise,” stated Christofer Mowry, CEO, General Fusion. “By locating at this campus, General Fusion expands our market presence beyond North America into Europe, broadening our global network of government, institutional, and industrial partners. This is incredibly exciting news for not only General Fusion, but also the global effort to develop practical fusion energy.”

The Culham Campus, the home of the UK’s national fusion research programme, is owned and managed by UKAEA, widely recognized as a world leader in fusion energy development and innovation.

“This is a great development for UKAEA, very much in line with our mission to lead the development of sustainable fusion energy, and builds on our long heritage of hosting major fusion facilities such as the Joint European Torus,” said Ian Chapman, CEO of UKAEA.

About General Fusion
General Fusion’s mission is to pursue the commercialization of fusion energy based on its proprietary Magnetized Target Fusion technology. The company is based in Vancouver, Canada, with locations in Washington, D.C., and London, U.K. The company was established in 2002 and is funded by a global syndicate of leading energy venture capital firms, industry leaders, and technology pioneers. General Fusion’s partnership with the UKAEA coincides with an expansion of the company’s global headquarters and research facilities in Vancouver, Canada, and a growing presence in the United States.

Twitter: @GeneralFusion         More information: www.generalfusion.com

Media contact:
Grace Peach
Director, Marketing and Communications
General Fusion
Email: media@generalfusion.com
Phone: 1-866-904-0995

About UK Atomic Energy Authority
The UK Atomic Energy Authority (UKAEA) carries out fusion energy research on behalf of the UK Government at Culham Science Centre near Oxford. UKAEA oversees Britain’s fusion programme, headed by the MAST Upgrade (Mega Amp Spherical Tokamak) experiment. It also hosts the world’s largest fusion research facility, JET (Joint European Torus), which it operates for European scientists under a contract with the European Commission.

Fusion research at Culham is funded by the Engineering & Physical Sciences Research Council (EPSRC) and by the European Union under the EURATOM treaty.

Twitter: @UKAEAofficial         More information: www.gov.uk/ukaea

Media contact:
Nick Holloway
UKAEA Media Manager
nick.holloway@ukaea.uk

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/10dddd6f-2034-4cca-98b8-be66f10b601b

เทเมคูลา, แคลิฟอร์เนีย, June 17, 2021 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (ต่อไปนี้ขอเรียกว่า “กลุ่ม”) บริษัทในเครือ Nikkiso Co., Ltd (ประเทศญี่ปุ่น) ภูมิใจที่จะประกาศว่าพวกเขาได้ลงนามในข้อตกลงเพื่อให้ Asas Aljood เป็นผู้ให้บริการที่ได้รับอนุญาตสำหรับ Nikkiso Cryogenic Services (NCS) ในราชอาณาจักรซาอุดิอาระเบีย

ด้วยการเติบโตของตลาดตะวันออกกลาง ข้อตกลงนี้จะช่วยให้กลุ่มเป็นที่รู้จักอย่างกว้างขวางในภูมิภาคของตนในด้านก๊าซสำหรับอุตสาหกรรม ไฮโดรเจน การแปรรูปก๊าซธรรมชาติและอุตสาหกรรมปิโตรเคมี ตั้งแต่วันที่ 1 กรกฎาคม 2021 เป็นต้นไป Asas Aljood จะใช้การประชุมเชิงปฏิบัติการในพื้นที่ของตนเพื่อส่งมอบบริการหลังการขายและการสนับสนุนสำหรับทั้งปั๊มและตัวขยายเทอร์โบ รวมถึงการบรรจุ การซ่อมแซม อะไหล่ และบริการภาคสนาม

Asas Aljood ตั้งอยู่ในเมืองดัมมาม จะให้บริการเพื่อให้ธุรกิจเป็นที่รู้จักมากขึ้นกว่าเดิมในภูมิภาคของเรา นอกเหนือจากการดำเนินงานในตะวันออกกลางของกลุ่มในเมืองชาร์จาห์ (UAE)

“ความร่วมมือครั้งใหม่นี้ระหว่าง Nikkiso และ Asas Aljood ทำให้เราเป็นที่รู้จักมากยิ่งขึ้นระดับภูมิภาคในซาอุดิอาระเบีย และเสริมความสามารถของเราในการให้บริการตลาดตะวันออกกลางได้ดียิ่งขึ้น” Jim Estes ประธานของ Nikkiso Cryogenic Services กล่าว “ผมหวังว่าจะยังคงให้บริการและการสนับสนุนที่มีคุณภาพสูงสุดแก่ลูกค้าของ Nikkiso ต่อไปโดยขจัดการขัดข้องของระบบที่มีค่าใช้จ่ายสูงในการดำเนินงานและกระบวนการของพวกเขา”

Asas Aljood เป็นผู้ให้บริการชั้นนำด้านบริการสนับสนุนและบำรุงรักษาในอุตสาหกรรมน้ำมันและก๊าซ ปิโตรเคมีและพลังงาน เป็นต้น

เกี่ยวกับ CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (ปัจจุบันเป็นสมาชิกของ Nikkiso Co., Ltd.) บริษัทสมาชิกผลิตอุปกรณ์แปรรูปก๊าซไครโอเจนทางวิศวกรรมและโรงงานที่มีกระบวนการขนาดเล็กสำหรับก๊าซธรรมชาติเหลว (LNG), บริการที่ดีและอุตสาหกรรมก๊าซสำหรับอุตสาหกรรม Cryogenic Industries ก่อตั้งขึ้นเมื่อ 50 ปีที่แล้ว เป็นบริษัทแม่ของ ACD, Cosmodyne และ Cryoquip และเป็นกลุ่มที่ควบคุมโดยทั่วไปซึ่งมีหน่วยงานปฏิบัติการประมาณ 20 แห่ง

สำหรับข้อมูลเพิ่มเติม โปรดไปที่ www.nikkisoCEIG.com และ www.nikkiso.com

ติดต่อด้านสื่อ:

Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

 

Dtravel addresses the sharing economy’s trust problem, giving hosts and guests more control, ownership, and lower fees than existing platforms.

SYDNEY, Australia, June 16, 2021 (GLOBE NEWSWIRE) — Former executives from Airbnb, Expedia, and other global technology companies have joined forces with Binance-backed Travala.com to launch Dtravel, a decentralized platform for the home-sharing economy facilitating short and long-term stays payable with cryptocurrency and traditional payment methods.

Dtravel is backed by a $5M seed fundraising round from Kenetic Capital, Future Perfect Ventures, DHVC, Plutus VC, GBV Capital, AU21 Capital, Shima Capital, LD Capital and NGC Ventures, as well as several angel investors.

Governed entirely by its community via the Dtravel Decentralized Autonomous Organization (DAO) and leveraging decentralized finance (DeFi) blockchain technology to facilitate smart contracts, Dtravel repairs the broken relationship between hosts and guests created by existing centralized home-sharing platforms to deliver the world’s first true sharing economy.

Dtravel is powered by its native token TRVL — coming soon to Binance Smart Chain and the Ethereum Network — which is held by all hosts and can be used for booking stays, staking to qualify for rewards, participating in platform governance, and more.

The first 100,000 hosts to register are eligible to receive over $35 million worth of TRVL tokens.

“Traditional home sharing platforms are aligned with their users in the early stages, but over time this changes. With the need to return profits to shareholders, home-sharing platforms are forced to extract as much as possible from transactions on their platforms,” said Juan Otero, co-founder and CEO of Travala.com. “Dtravel meets the needs of the home-sharing community first and forever. It’s easy-to-use, highly secure, and optimized for the next generation of hosts and guests looking to take back control of their travel experience.”

The Problem: Too Much Control in the Hands of Too Few
Over the past decade, a limited number of corporations have risen to dominate the home-sharing economy. Though this structure has led to dramatic growth of the home-sharing economy, it has done so at a cost, including:

• High fees – existing players charge fees up to 20% of the total booking cost
• Centralized and controlled communications – loss of direct host-guest relationships
• Transactional processes, not relationships – a shift from encouraging high-value, peer-to-peer relationships to transactional ones
• Lower levels of trust – trust between hosts and guests, as well as towards the platforms themselves, has been eroded
• Payment options – existing players don’t accept payment in cryptocurrencies

The Dtravel Solution: Community-governed, Peer-to-peer, DeFi Native
Dtravel aims to replace the broken relationship between centralized home-sharing corporations and their hosts and guests by putting ownership, control, and decision making back into the hands of users through blockchain technology. In doing so, Dtravel can:

• Reduce fees – instead of fees as high as 20%, fees on Dtravel are only 7.5%
• Give a voice back to the community – the Dtravel DAO enables hosts and guests to directly influence the direction, operations and governance of Dtravel
• Expand payment options – enable various cryptocurrencies, including Bitcoin, to be used for payments that lower the cost of transacting compared to traditional payment methods
• Align interests – instead of being forced into an extraction imperative common with centralized platforms, use a token to align economic interests of users
• Provide peace of mind – Dtravel will have a Protection Pool which offers Hosts up to $1,000,000 in property protection
• Create additional revenue streams – users can earn additional revenue by referring hosts and guests, as well as by participating in user support, community forums and troubleshooting

“Sharing economies are authentic and sustainable only when they are governed and controlled by stakeholders, and the home-sharing ecosystem has been broken for years under outsized control from centralized corporations. It’s time for a community-owned and community-governed replacement,” said Jalak Jobanputra, Founding Partner of Future/Perfect Ventures.

“With travel starting to rebound and a record level of interest in blockchain technologies like cryptocurrencies, Dtravel gives eager people what has been missing to date: control and ownership over their own travel experiences. By allowing guests and hosts full participation in their experiences and in the economy they are creating, Dtravel fulfills the true mission of sharing economies.”

For more information and to become a host please visit: Dtravel.com

About Dtravel
Dtravel replaces the broken home-sharing economy with a decentralized network that diverts control away from corporations and back into the hands of hosts and guests. Dtravel is built on decentralized finance (DeFi) blockchain technology, owned and governed by its community through the Dtravel Decentralized Autonomous Organization (DAO) and powered by the network’s native token TRVL, bringing more transparency and significantly lower fees to the short- and long-term home rental market.

Joe@serotonin.io